Werner Rabitsch

Werner Rabitsch

Auto-generated profile, based on publicly available information

Werner Rabitsch

Department of Internal Medicine I, Bone Marrow Transplantation Unit, Medical University of Vienna , 1090 Vienna

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JSJohanna Strobl
Johanna Strobl
LGLaura Marie Gail
Laura Marie Gail
LKLisa Kleißl
Lisa Kleißl
RPRam Vinay Pandey
Ram Vinay Pandey
VSValerie Smejkal
Valerie Smejkal
GSGeorg Stary
Georg Stary
Emigration of tissue-resident memory T cells (TRMs) was recently introduced in mouse models and may drive systemic inflammation. Skin TRMs of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) can coexist beside donor T cells, offering a unique human model system to study T cell migration. By genotyping, mathematical modeling, single-cell transcriptomics, and functional analysis of patient blood and skin T cells, we detected a small consistent population of circulating skin-derived T cells with a TRM phenotype (cTRMs) in the blood and unveil their skin origin and striking resemblance to skin TRMs. Blood from patients with active graft-versus-host disease (GVHD) contains elevated numbers of host cTRMs producing pro-inflammatory Th2/Th17 cytokines and mediating keratinocyte damage. Expression of gut-homing receptors and the occurrence of cTRMs in gastrointestinal GVHD lesions emphasize their potential to reseed and propagate inflammation in distant organs. Collectively, we describe a distinct circulating T cell population mirroring skin inflammation, which could serve as a biomarker or therapeutic target in GVHD.

5 December 2014 in Transplant International
Verified
Journal Article
Closed access
PDF file
PSPeter Schellongowski
Peter Schellongowski
KRKatharina Riss
Katharina Riss
TSThomas Staudinger
Thomas Staudinger
RURoman Ullrich
Roman Ullrich
CKClaus G. Krenn
Claus G. Krenn
GLGyörgy Lang
György Lang
In patients awaiting lung transplantation (LTX), adequate gas exchange may not be sufficiently achieved by mechanical ventilation alone if acute respiratory decompensation arises. We report on 20 patients with life-threatening hypercapnia who received extracorporeal CO2 removal (ECCO2-R) by means of the interventional lung assist (ILA®, Novalung) as bridge to LTX. The most common underlying diagnoses were bronchiolitis obliterans syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis, respectively. The type of ILA was pumpless arteriovenous or pump-driven venovenous (ILA activve®, Novalung) in 10 patients each. ILA bridging was initiated in 15 invasively ventilated and five noninvasively ventilated patients, of whom one had to be intubated prior to LTX. Hypercapnia and acidosis were effectively corrected in all patients within the first 12 h of ILA therapy: PaCO2 declined from 109 (70-146) to 57 (45-64) mmHg, P < 0.0001; pH increased from 7.20 (7.06-7.28) to 7.39 (7.35-7.49), P < 0.0001. Four patients were switched to extracorporeal membrane oxygenation due to progressive hypoxia or circulatory failure. Nineteen patients (95%) were successfully transplanted. Hospital and 1-year survival was 75 and 72%, respectively. Bridging to LTX with ECCO2-R delivered by arteriovenous pumpless or venovenous pump-driven ILA is feasible and associated with high transplantation and survival rates.

27 November 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JSJohanna Strobl
Johanna Strobl
LGLaura M Gail
Laura M Gail
LKLaura Krecu
Laura Krecu
SMShaista Madad
Shaista Madad
LKLisa Kleißl
Lisa Kleißl
GSGeorg Stary
Georg Stary
Graft-versus-host disease (GvHD) is a major life-threatening complication of allogeneic haematopoietic stem cell transplantation (HSCT), limiting the broad application of HSCT for haematological malignancies. Cutaneous GvHD is described as a post-transplant inflammatory reaction by skin-infiltrating donor T cells and remaining recipient tissue-resident memory T cells. Despite the major influence of lymphocytes on GvHD pathogenesis, the complex role of mononuclear phagocytes (MNPs) in tissues affected by GvHD is increasingly appreciated. To characterize the identity, origin and functions of MNPs in patients with acute cutaneous GvHD. Using single-cell RNA sequencing and multiplex tissue immunofluorescence, we identified an increased abundance of MNPs in skin and blood from 36 patients with acute cutaneous GvHD. In cases of sex-mismatched transplantation, we used expression of X-linked genes to detect rapid tissue adaptation of newly recruited donor MNPs resulting in similar transcriptional states of host- and donor-derived macrophages within GvHD skin lesions. We showed that cutaneous GvHD lesions harbour expanded CD163+ tissue-resident macrophage populations with anti-inflammatory and tissue-remodelling properties including interleukin-10 cytokine production. Cell–cell interaction analyses revealed putative signalling to strengthen regulatory T-cell responses. Notably, macrophage polarization in chronic cutaneous GvHD types was proinflammatory and drastically differed from acute GvHD, supporting the notion of distinct cellular players in different clinical GvHD subtypes. Overall, our data reveal a surprisingly dynamic role of MNPs after HSCT. Specific and time-resolved targeting to repolarize this cell subset may present a promising therapeutic strategy in combatting GvHD skin inflammation.

1 November 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JSJohanna Strobl
Johanna Strobl
RPRam Vinay Pandey
Ram Vinay Pandey
TKThomas Krausgruber
Thomas Krausgruber
LKLisa Kleißl
Lisa Kleißl
BRBärbel Reininger
Bärbel Reininger
GSGeorg Stary
Georg Stary

1 January 2001 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
KLKlaus Laczika
Klaus Laczika
GMGerlinde Mitterbauer
Gerlinde Mitterbauer
MMMargit Mitterbauer
Margit Mitterbauer
PKPaul N. Knoebl
Paul N. Knoebl
ISIlse Schwarzinger
Ilse Schwarzinger
UJUlrich Jaeger
Ulrich Jaeger
Minimal residual disease in patients with acute myeloid leukemia (AML) with inversion(16) can be monitored by CBFβ/MYH11 RT-PCR. While the association between molecular remission (MR) in bone marrow (BM) and peripheral blood (PB) and long-term clinical remission (CR) seems to be established, there are insufficient data on the kinetics of CBFβ/MYH11. We have performed a prospective study in order to generate a reasonable and sufficient schedule for PCR-monitoring. 11 patients with AML and inversion (16) in complete hematological remission have been prospectively monitored by CBFβ/MYH11 RT-PCR in their BM and PB during an observation period of 7 to 67 months (median 32 months). Patients were followed during consolidation chemotherapy with repetitive cycles of high-dose Ara-C and after autologous or allogeneic stem cell transplantation in 2nd CR or refractory AML. MR never coincided with achievement of CR but occurred between 2 and 8 months after hematological remission. All patients in continuous CR were PCR-negative after 1–8 (median 4) months. Two patients relapsed despite MR for 10 to 15 months. Molecular relapse preceded hematological relapse by 3 to 5 months. Three out of four patients who were not in MR after 8 months relapsed. Allogeneic stem cell transplantation was able to eradicate minimal residual disease in 4/4 patients. In 2 patients a temporary reconversion to PCR-positivity was reversed by reduction of immunosuppression. 1 patient did not become PCR-negative until compete withdrawal of immunosuppression. We suggest that BM and PB should be examined after the last consolidation treatment. In case of MR, PB should be examined every 1 to 2 months and BM examination should be done only in case of PCR-positivity in PB in order to confirm the molecular relapse and to identify an impending cytogenetic and/or hematological relapse. CBFβ/MYH11 RT-PCR monitoring is able to predict relapse 3 to 5 months prior to overt hematological relapse, offers a window of opportunity for preemptive therapy of molecular relapse and confers implications for immunotherapy in the setting of allografting.

18 April 2000 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
HGH. T. Greinix
H. T. Greinix
HLH. Loidolt
H. Loidolt
WRW. Rabitsch
W. Rabitsch
ASAxel Schulenburg
Axel Schulenburg
FKF. Keil
F. Keil
PKP. Kalhs
P. Kalhs